Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B
Article first published online: 12 FEB 2007
Alimentary Pharmacology & Therapeutics
Volume 25, Issue 8, pages 891–898, April 2007
How to Cite
CHAN, H. L.-Y., WONG, V. W.-S., TSE, C.-H., CHIM, A. M.-L., CHAN, H.-Y., WONG, G. L.-H. and SUNG, J. J.-Y. (2007), Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 25: 891–898. doi: 10.1111/j.1365-2036.2007.03272.x
- Issue published online: 30 MAR 2007
- Article first published online: 12 FEB 2007
- Publication data Submitted 19 January 2007 First decision 26 January 2007 Resubmitted 29 January 2007 Accepted 31 January 2007
- 7Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006; 1: 229–30A., , , , , .
- 21Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (The GLOBE Study). Hepatology 2005; 42(supp1): 232–233A., , , et al.
- 22Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42(Suppl. 2): 17., , , et al.
- 26Therapy with adefovir alone or combined with lamivudine in patients with lamivudine-resistant chronic hepatitis B: Clinical and virological aspects. Hepatology 2006; 44(Suppl. 1): 231A., , , et al.
- 27Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006; 44(Suppl. 1): 693–4A., , , et al.